Tempus AI shares fell 4.49% to $76.75 Friday, pulling back after a sharp multi-day rally driven by CEO Eric Lefkofsky’s reimbursement outlook. The decline came as the Nasdaq slipped 0.09%, the S&P 500 fell 0.47% and the healthcare sector declined about 0.5%. Tempus said FDA approval of the tumor-only version of its solid-tumor assay allows ADLT pricing at $4,500, matching tumor-normal testing, with all solid-tumor assays expected to use that structure beginning Jan. 1. Lefkofsky estimated the change could provide $80 million to $100 million in revenue and margin benefit. Tempus expects approval and pricing for its liquid-biopsy test in the second half of 2027, potentially lifting reimbursement from about $3,200 to the mid-to-high $7,000 range and adding another $250 million to $300 million in revenue and margin benefit. The stock remained about 16% above its 20-day moving average and 35% above its 50-day average, with resistance near $79 and support around $61.50. The latest source gives Tempus a Hold consensus, while citing HC Wainwright’s Buy rating and $66 forecast, UBS’s Neutral rating and $70 forecast, and Rothschild’s Neutral rating and $67 forecast. Tempus has notable exposure in ARKK, ARKG and THNQ, where it represents about 4.16%, 8.04% and 2.86%, respectively.